"Lightweight Cabin" makes its debut at the 8th Import Expo, announcing multiple collaborations with ecological partners along the way, sponsored by Novo Nordisk A/S Class B ADR (NVO.US).

At the 8th China International Import Expo, the first immersive experience space focusing on obesity health management, "Light House", created by Novo Nordisk A/S Sponsored ADR Class B, the eight-year "Perfect Attendance Student", became the highlight of the event. In addition, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) debuted new developments of several star products from the semaglutide family at the Import Expo, and announced multiple collaborations. These initiatives demonstrate Novo Nordisk A/S Sponsored ADR Class B's firm commitment to deepening its presence in the Chinese market and building an innovative ecosystem with local partners. The debut of "Light House" marks a revolutionary experience in cognitive management from awareness This year at the Import Expo, the "Light House" created by Novo Nordisk A/S Sponsored ADR Class B breaks the traditional model of one-way dissemination of disease knowledge, bringing the complete cycle of "cognitive enhancement - scientific treatment - long-term management" to the stage for the first time. This immersive experience space aims to push the public from "passive reception of obesity knowledge" to "active learning and proactive management," further enhancing the scientific understanding of obesity as a chronic disease that requires professional diagnosis and treatment. In the "cognitive enhancement" scene, the public can use AI visual recognition and interactive technology to see "themselves gaining weight", combined with corresponding health risk prompts, to intuitively experience the potential threat of obesity to health. The "scientific treatment" section showcases a new model of "hospital and retail drugstore collaboration" to help bridge the gap between in-hospital and out-of-hospital management of obesity. As an important means of treating obesity, GLP-1 class weight reduction drugs represented by semaglutide have brought new breakthroughs to clinical treatment. The "long-term management" scene relies on Novo Nordisk A/S Sponsored ADR Class B's digital patient service platform "Nuohe Care" to demonstrate the important role of digital tools in the long-term management of obesity. New developments of the semaglutide family bring multiple benefits to patients Novo Nordisk A/S Sponsored ADR Class B is the "Perfect Attendance Student" at the Import Expo and a typical representative of the Expo's overflow effect. The semaglutide molecules that were exhibited in the form of literature at the first Import Expo are now introduced to the Chinese market with three products, making the Import Expo an accelerator for Novo Nordisk A/S Sponsored ADR Class B's innovative products to go from "exhibits to commodities, and from commodities to popular products." The development of semaglutide molecules has made a historic breakthrough in the treatment of diabetes and obesity. At this year's Import Expo, multiple products from the "semaglutide family" showcased their latest progress and multiple clinical benefits. Among them, Nuohe Ying (semaglutide injection for long-term weight management) included cardiovascular benefit results in China's instructions in April this year. Real-world research shows that after being treated with Nuohe Ying, respondents experienced a significant reduction of 46% in the "food noise" they encountered. In addition, the product has been approved in the United States for the treatment of metabolic-associated fatty liver disease (MASH), becoming the first and only GLP-1 drug approved for this indication. Nuohe Tai (semaglutide injection) was approved for additional indications of chronic kidney disease (CKD) in China in July this year, becoming a medication for three major indications including type 2 diabetes, cardiovascular disease, and chronic kidney disease, helping patients achieve "sugar-heart-kidney" co-management and co-treatment. The world's first oral peptide GLP-1RA Nuohe Xin (semaglutide tablet) has broken the technical barrier of oral peptide drugs, significantly improving the convenience of medication for patients. The product was approved in China in 2024 and made its "first exhibition in China" at the seventh Import Expo, with a full launch scheduled for January 2025. At this year's Import Expo, Novo Nordisk A/S Sponsored ADR Class B exhibited 13 innovative drugs, 3 injection devices, and 2 clinical research literature, including the innovative combination drug IcoSema, the world's first basal insulin weekly formulation with GLP-1RA weekly formulation, and the clinical research literature for the long-acting growth hormone injection Somapacitan to be taken once a week. Deepening local cooperation to build an innovative ecosystem The Import Expo is not only a stage for the debut of innovative products but also the preferred platform to announce major collaborations. This year, Novo Nordisk A/S Sponsored ADR Class B's China Open Innovation Center was officially established and received a license from the Shanghai Pudong New Area Government, joining the Pudong "Large Enterprise Open Innovation Center (GOI)" plan. The center will work with the Tianjin production base, Beijing R&D center, and Shanghai commercial operations and innovation engine, driving collaborative innovation along the entire industry chain. During the Import Expo, Novo Nordisk A/S Sponsored ADR Class B signed a strategic cooperation agreement with the Shanghai Clinical Innovation Transformation Research Institute, and the two parties will deepen cooperation in the areas of clinical innovation achievement transformation, disease clinical cohort construction, real-world research, and big data mining, to promote the transformation of clinical research achievements in Shanghai. In the digital field, Novo Nordisk A/S Sponsored ADR Class B announced the expansion and upgrade of the "Health Ecosystem Alliance" set to be established in 2023, and deepened cooperation with platforms such as JD HEALTH, ALI HEALTH, Tencent Health, PA GOODDOCTOR, and FANGZHOU JIANKE, to jointly build a digital chronic disease management ecosystem. Additionally, the "Nuohe Care" platform launched the Hongmeng APP and a special edition for weight loss, further expanding service boundaries to empower patients in long-term chronic disease management. On the retail end, Novo Nordisk A/S Sponsored ADR Class B actively supported the preparation and implementation of the "Retail Pharmacy Obesity Health Management Norms" and partnered with retail pharmacies to build "Obesity Retail Pharmacy Light Houses," bridging the "last mile" of obesity management and bringing professional health services closer to patients' daily lives. This year, the "Light House" has been piloted and will be further expanded to increase service coverage. Eight years of accompanying the Import Expo, jointly building a healthy future Zhou Xiaoping, Senior Vice President and Greater China President of Novo Nordisk A/S Sponsored ADR Class B, said, "Novo Nordisk A/S Sponsored ADR Class B has been a long-time friend of the Import Expo for eight years, and we clearly see the overflow effect of the Expo and the incentive for biomedical innovation. The Import Expo is also an important platform for expanding our circle of friends. In the future, Novo Nordisk A/S Sponsored ADR Class B will continue to fulfill its long-term commitment to patients through innovation and collaboration, contributing to the construction of a 'Healthy China.'" From the experiential scene of "Light House" to the breakthroughs of the semaglutide family, to the ecological co-construction of digitalized and retail pharmacies, Novo Nordisk A/S Sponsored ADR Class B's showcase at the 8th Import Expo is not just a demonstration of the innovative strength of a biopharmaceutical company, but also a long-term commitment to "in China, for China, benefiting the world."